Skip to main content
Top
Published in: Orphanet Journal of Rare Diseases 1/2013

Open Access 01-12-2013 | Research

Assessment and management of pulmonary alveolar proteinosis in a reference center

Authors: Ilaria Campo, Francesca Mariani, Giuseppe Rodi, Elena Paracchini, Eric Tsana, Davide Piloni, Isabella Nobili, Zamir Kadija, Angelo Corsico, Isa Cerveri, Claudia Chalk, Bruce C Trapnell, Antonio Braschi, Carmine Tinelli, Maurizio Luisetti

Published in: Orphanet Journal of Rare Diseases | Issue 1/2013

Login to get access

Abstract

Pulmonary alveolar proteinosis (PAP) is a term defining an ultra-rare group of disorders characterised by a perturbation in surfactant homeostasis, resulting in its accumulation within airspaces and impaired gas transfer. In this report we provide data from a cohort of PAP patients (n = 81) followed for more than two decades at the San Matteo University Hospital of Pavia, Italy. In agreement with other large series in PAP individuals, 90% of the study subjects were affected by autoimmune/idiopathic PAP, while the remaining subjects were divided as follow: congenital 1%, secondary 4% and PAP-like 5%. The disease affected males and females with a ratio of 2:1 and approximately one third of PAP patients were lifelong nonsmokers. Occupational exposure was reported in 35% of subjects in this series. With reference to the PAP clinical course, in 29 patients (7% with spontaneous remission) disease severity did not necessitate whole lung lavage (WLL) in the long-term follow up. On the other hand, 44 PAP patients underwent therapeutic WLL: in 31 subjects a single WLL was sufficient to provide long term, durable benefit, whereas 13 patients required multiple WLLs. The intra-patient mean interval between two consecutive WLLs was 15.7 ± 13.6 months. When baseline data among never lavaged and PAP patients lavaged at least once were compared, the need for lavage was significantly associated with serum biomarkers (CEA, Cyfra, LDH), lung function parameters forced vital capacity (FVC), and lung diffusing capacity (Dlco). We conclude that patient cohorts with an ultra-rare disease, such as PAP, referred to a single reference center, can provide useful information on the natural history and clinical course of the disease.
Appendix
Available only for authorised users
Literature
1.
go back to reference Luisetti M, Trapnell BC: Pulmonary alveolar proteinosis. Interstitial Lung Disease. Edited by: Schwarz MI, King TE. Shelton CT: Peoples’ Medical Publishing House USA; 2010:1079-1093. Luisetti M, Trapnell BC: Pulmonary alveolar proteinosis. Interstitial Lung Disease. Edited by: Schwarz MI, King TE. Shelton CT: Peoples’ Medical Publishing House USA; 2010:1079-1093.
2.
go back to reference Trapnell BC, Whitsett JA, Nakata K: Pulmonary alveolar proteinosis. N Engl J Med. 2003, 349 (26): 2527-2539. 10.1056/NEJMra023226.PubMedCrossRef Trapnell BC, Whitsett JA, Nakata K: Pulmonary alveolar proteinosis. N Engl J Med. 2003, 349 (26): 2527-2539. 10.1056/NEJMra023226.PubMedCrossRef
4.
go back to reference Kitamura T, Tanaka N, Watanabe J, Uchida K, Kanegasaki S, Yamada Y, Nakata K: Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J Exp Med. 1999, 190 (6): 875-880. 10.1084/jem.190.6.875.PubMedCentralPubMedCrossRef Kitamura T, Tanaka N, Watanabe J, Uchida K, Kanegasaki S, Yamada Y, Nakata K: Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor. J Exp Med. 1999, 190 (6): 875-880. 10.1084/jem.190.6.875.PubMedCentralPubMedCrossRef
5.
go back to reference Tanaka N, Watanabe J, Kitamura T, Yamada Y, Kanegasaki S, Nakata K: Lungs of patients with idiopathic pulmonary alveolar proteinosis express a factor which neutralizes granulocyte-macrophage colony stimulating factor. FEBS Lett. 1999, 442 (2–3): 246-250.PubMedCrossRef Tanaka N, Watanabe J, Kitamura T, Yamada Y, Kanegasaki S, Nakata K: Lungs of patients with idiopathic pulmonary alveolar proteinosis express a factor which neutralizes granulocyte-macrophage colony stimulating factor. FEBS Lett. 1999, 442 (2–3): 246-250.PubMedCrossRef
6.
go back to reference Luisetti M, Kadija Z, Mariani F, Rodi G, Campo I, Trapnell BC: Therapy options in pulmonary alveolar proteinosis. Ther Adv Respir Dis. 2010, 4: 239-248. 10.1177/1753465810378023.PubMedCrossRef Luisetti M, Kadija Z, Mariani F, Rodi G, Campo I, Trapnell BC: Therapy options in pulmonary alveolar proteinosis. Ther Adv Respir Dis. 2010, 4: 239-248. 10.1177/1753465810378023.PubMedCrossRef
7.
go back to reference Ramirez J, Schultz R, Dutton R: Pulmonary alveolar proteinosis: a New technique and rationale for treatment. Arch Intern Med. 1963, 112: 419-431. 10.1001/archinte.1963.03860030173021.PubMedCrossRef Ramirez J, Schultz R, Dutton R: Pulmonary alveolar proteinosis: a New technique and rationale for treatment. Arch Intern Med. 1963, 112: 419-431. 10.1001/archinte.1963.03860030173021.PubMedCrossRef
8.
go back to reference Seymour JF, Presneill JJ, Schoch OD: Therapeutic efficacy of granulocyte macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis. Am J Respir Crit Care Med. 2001, 163: 524-531.PubMedCrossRef Seymour JF, Presneill JJ, Schoch OD: Therapeutic efficacy of granulocyte macrophage colony-stimulating factor in patients with idiopathic acquired alveolar proteinosis. Am J Respir Crit Care Med. 2001, 163: 524-531.PubMedCrossRef
9.
go back to reference Prakash UB, Barham SS, Carpenter HA, Dines DE, Marsh HM: Pulmonary alveolar phospholipoproteinosis: experience with 34 cases and a review. Mayo Clin Proc. 1987, 62 (6): 499-518. 10.1016/S0025-6196(12)65477-9.PubMedCrossRef Prakash UB, Barham SS, Carpenter HA, Dines DE, Marsh HM: Pulmonary alveolar phospholipoproteinosis: experience with 34 cases and a review. Mayo Clin Proc. 1987, 62 (6): 499-518. 10.1016/S0025-6196(12)65477-9.PubMedCrossRef
10.
go back to reference Inoue Y, Trapnell BC, Tazawa R, Arai T, Takada T, Hizawa N, Kasahara Y, Tatsumi K, Hojo M, Ichiwata T, Tanaka N, Yamaguchi E, Eda R, Oishi K, Tsuchihashi Y, Kaneko C, Nukiwa T, Sakatani M, Krischer JP, Nakata K, Japanese center of the rare lung diseases consortium: Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in japan. Am J Respir Crit Care Med. 2008, 177 (7): 752-762. 10.1164/rccm.200708-1271OC.PubMedCentralPubMedCrossRef Inoue Y, Trapnell BC, Tazawa R, Arai T, Takada T, Hizawa N, Kasahara Y, Tatsumi K, Hojo M, Ichiwata T, Tanaka N, Yamaguchi E, Eda R, Oishi K, Tsuchihashi Y, Kaneko C, Nukiwa T, Sakatani M, Krischer JP, Nakata K, Japanese center of the rare lung diseases consortium: Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in japan. Am J Respir Crit Care Med. 2008, 177 (7): 752-762. 10.1164/rccm.200708-1271OC.PubMedCentralPubMedCrossRef
11.
go back to reference Xu Z, Jing J, Wang H, Xu F, Wang J: Pulmonary alveolar proteinosis in China: a systematic review of 241 cases. Respirology. 2009, 14 (5): 761-766. 10.1111/j.1440-1843.2009.01539.x.PubMedCrossRef Xu Z, Jing J, Wang H, Xu F, Wang J: Pulmonary alveolar proteinosis in China: a systematic review of 241 cases. Respirology. 2009, 14 (5): 761-766. 10.1111/j.1440-1843.2009.01539.x.PubMedCrossRef
12.
go back to reference Bonella F, Bauer PC, Griese M, Ohshimo S, Guzman J, Costabel U: Pulmonary alveolar proteinosis: new insights from a single-center cohort of 70 patients. Respir Med. 2011, 105 (12): 1908-1916. 10.1016/j.rmed.2011.08.018.PubMedCrossRef Bonella F, Bauer PC, Griese M, Ohshimo S, Guzman J, Costabel U: Pulmonary alveolar proteinosis: new insights from a single-center cohort of 70 patients. Respir Med. 2011, 105 (12): 1908-1916. 10.1016/j.rmed.2011.08.018.PubMedCrossRef
13.
go back to reference Morbini P, Guddo F, Contini P, Luisetti M, Schiavina M, Zompatori M: Rare diffuse diseases of the lung. Pulmonary alveolar proteinosis, lymphangioleiomyomatosis, amyloidosis. Pathologica. 2010, 102: 547-556.PubMed Morbini P, Guddo F, Contini P, Luisetti M, Schiavina M, Zompatori M: Rare diffuse diseases of the lung. Pulmonary alveolar proteinosis, lymphangioleiomyomatosis, amyloidosis. Pathologica. 2010, 102: 547-556.PubMed
14.
go back to reference Beccaria M, Luisetti M, Rodi G, Corsico A, Zoia MC, Colato S, Pochetti P, Braschi A, Pozzi E, Cerveri I: Long term durable benefit after whole lung lavage in pulmonary alveolar proteinosis. Eur Respir J. 2004, 23: 526-531. 10.1183/09031936.04.00102704.PubMedCrossRef Beccaria M, Luisetti M, Rodi G, Corsico A, Zoia MC, Colato S, Pochetti P, Braschi A, Pozzi E, Cerveri I: Long term durable benefit after whole lung lavage in pulmonary alveolar proteinosis. Eur Respir J. 2004, 23: 526-531. 10.1183/09031936.04.00102704.PubMedCrossRef
15.
go back to reference Inoue Y, Nakata K, Arai T, Tazawa R, Hamano E, Nukiwa T, Kudo K, Keicho N, Hizawa N, Yamaguchi E, Eda R, Oishi K, Maeda Y, Koreeda Y, Kodo N, Sakatani M: Epidemiological and clinical features of idiopathic pulmonary alveolar proteinosis in Japan. Respirology. 2006, 11: S55-S60. 10.1111/j.1440-1843.2006.00810.x.PubMedCrossRef Inoue Y, Nakata K, Arai T, Tazawa R, Hamano E, Nukiwa T, Kudo K, Keicho N, Hizawa N, Yamaguchi E, Eda R, Oishi K, Maeda Y, Koreeda Y, Kodo N, Sakatani M: Epidemiological and clinical features of idiopathic pulmonary alveolar proteinosis in Japan. Respirology. 2006, 11: S55-S60. 10.1111/j.1440-1843.2006.00810.x.PubMedCrossRef
16.
go back to reference Cummings KJ, Donat WE, Ettensohn DB, Roggli VL, Ingram P, Kreiss K: Pulmonary alveolar proteinosis in workers at an indium processing facility. Am J Respir Crit Care Med. 2010, 181 (5): 458-464. 10.1164/rccm.200907-1022CR.PubMedCentralPubMedCrossRef Cummings KJ, Donat WE, Ettensohn DB, Roggli VL, Ingram P, Kreiss K: Pulmonary alveolar proteinosis in workers at an indium processing facility. Am J Respir Crit Care Med. 2010, 181 (5): 458-464. 10.1164/rccm.200907-1022CR.PubMedCentralPubMedCrossRef
17.
go back to reference Suzuki T, Sakagami T, Young LR, Carey BC, Wood RE, Luisetti M, Wert SE, Rubin BK, Kevill K, Chalk C, Whitsett JA, Stevens C, Nogee LM, Campo I, Trapnell BC: Hereditary pulmonary alveolar proteinosis. Pathogenesis, presentation, diagnosis, and therapy. Am J Respir Crit Care Med. 2010, 182: 1292-1304. 10.1164/rccm.201002-0271OC.PubMedCentralPubMedCrossRef Suzuki T, Sakagami T, Young LR, Carey BC, Wood RE, Luisetti M, Wert SE, Rubin BK, Kevill K, Chalk C, Whitsett JA, Stevens C, Nogee LM, Campo I, Trapnell BC: Hereditary pulmonary alveolar proteinosis. Pathogenesis, presentation, diagnosis, and therapy. Am J Respir Crit Care Med. 2010, 182: 1292-1304. 10.1164/rccm.201002-0271OC.PubMedCentralPubMedCrossRef
18.
go back to reference Barilli A, Rotoli BM, Visigalli R, Bussolati O, Gazzola GC, Kadija Z, Rodi G, Mariani F, Ruzza ML, Luisetti M, Dall'Asta V: In Lysinuric protein Intolerance system y + L activity is defective in monocytes and in GM-CSF-differentiated macrophages. Orphanet J Rare Dis. 2010, 5: 32-10.1186/1750-1172-5-32.PubMedCentralPubMedCrossRef Barilli A, Rotoli BM, Visigalli R, Bussolati O, Gazzola GC, Kadija Z, Rodi G, Mariani F, Ruzza ML, Luisetti M, Dall'Asta V: In Lysinuric protein Intolerance system y + L activity is defective in monocytes and in GM-CSF-differentiated macrophages. Orphanet J Rare Dis. 2010, 5: 32-10.1186/1750-1172-5-32.PubMedCentralPubMedCrossRef
19.
go back to reference Ceruti M, Rodi G, Stella GM, Adami A, Bolongaro A, Baritussio A, Pozzi E, Luisetti M: Successful whole lung lavage in pulmonary alveolar proteinosis secondary to lysinuric protein intolerance: a case report. Orphanet J Rare Dis. 2007, 2: 14-10.1186/1750-1172-2-14.PubMedCentralPubMedCrossRef Ceruti M, Rodi G, Stella GM, Adami A, Bolongaro A, Baritussio A, Pozzi E, Luisetti M: Successful whole lung lavage in pulmonary alveolar proteinosis secondary to lysinuric protein intolerance: a case report. Orphanet J Rare Dis. 2007, 2: 14-10.1186/1750-1172-2-14.PubMedCentralPubMedCrossRef
20.
go back to reference Hirakata Y, Kobayashi J, Sugama Y, Kitamura S: Elevation of tumour markers in serum and bronchoalveolar lavage fluid in pulmonary alveolar proteinosis. Eur Respir J. 1995, 8: 689-696.PubMed Hirakata Y, Kobayashi J, Sugama Y, Kitamura S: Elevation of tumour markers in serum and bronchoalveolar lavage fluid in pulmonary alveolar proteinosis. Eur Respir J. 1995, 8: 689-696.PubMed
21.
go back to reference Fujishima T, Honda Y, Shijubo N, Takahashi H, Abe S: Increased carcinoembryonic antigen concentrations in sera and bronchoalveolar lavage fluids of patients with pulmonary alveolar proteinosis. Respiration. 1995, 626: 317-321.CrossRef Fujishima T, Honda Y, Shijubo N, Takahashi H, Abe S: Increased carcinoembryonic antigen concentrations in sera and bronchoalveolar lavage fluids of patients with pulmonary alveolar proteinosis. Respiration. 1995, 626: 317-321.CrossRef
Metadata
Title
Assessment and management of pulmonary alveolar proteinosis in a reference center
Authors
Ilaria Campo
Francesca Mariani
Giuseppe Rodi
Elena Paracchini
Eric Tsana
Davide Piloni
Isabella Nobili
Zamir Kadija
Angelo Corsico
Isa Cerveri
Claudia Chalk
Bruce C Trapnell
Antonio Braschi
Carmine Tinelli
Maurizio Luisetti
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2013
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/1750-1172-8-40

Other articles of this Issue 1/2013

Orphanet Journal of Rare Diseases 1/2013 Go to the issue